Gain Historical Balance Sheet

GANX Stock

USD 1.91 0.09 4.50%

Trend analysis of Gain Therapeutics balance sheet accounts such as Other Liabilities of 179.3 K or Net Tangible Assets of 12.8 M provides information on Gain Therapeutics' total assets, liabilities, and equity, which is the actual value of Gain Therapeutics to its prevalent stockholders. By breaking down trends over time using Gain Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Gain Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Gain Therapeutics is a good buy for the upcoming year.

Gain Therapeutics Inventory

1.64 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

About Gain Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Gain Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Gain Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Gain Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Gain currently owns. An asset can also be divided into two categories, current and non-current.

Gain Therapeutics Balance Sheet Chart

At this time, Gain Therapeutics' Cash is fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.3 M in 2025, whereas Other Liabilities is likely to drop slightly above 179.3 K in 2025.

Other Current Liab Total Current Liabilities Other Liab Accounts Payable

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Gain Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Gain Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Gain Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Gain Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Gain Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Gain Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.At this time, Gain Therapeutics' Cash is fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.3 M in 2025, whereas Other Liabilities is likely to drop slightly above 179.3 K in 2025.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	4.1M	4.9M	5.7M	6.0M
Other Current Liabilities	2.0M	2.1M	2.4M	2.5M

Total Current Liabilities Other Current Liab

Gain Therapeutics balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total
Other Current Liab		1.0	0.71	0.79	-0.98	0.9	0.81	0.94	0.85	0.96	0.99	0.77	0.98	-0.2	0.8	0.83	0.74	0.82	0.71	-0.53	0.61	0.73	0.86	0.78	0.97	0.82
Total Current Liabilities	1.0		0.7	0.76	-0.98	0.89	0.8	0.96	0.86	0.97	0.98	0.74	0.98	-0.22	0.77	0.81	0.7	0.79	0.75	-0.51	0.59	0.68	0.86	0.75	0.96	0.81
Other Liab	0.71	0.7		0.92	-0.64	0.65	0.86	0.6	0.8	0.62	0.76	0.93	0.73	0.47	0.93	0.92	0.92	0.93	0.29	-0.9	0.92	0.61	0.86	0.93	0.8	0.93
Net Tangible Assets	0.79	0.76	0.92		-0.75	0.74	0.84	0.67	0.72	0.72	0.85	0.99	0.82	0.38	0.99	0.92	0.98	0.96	0.35	-0.91	0.93	0.7	0.85	0.99	0.89	0.92
Retained Earnings	-0.98	-0.98	-0.64	-0.75		-0.88	-0.74	-0.95	-0.82	-0.97	-0.97	-0.71	-0.97	0.27	-0.74	-0.74	-0.67	-0.74	-0.77	0.49	-0.56	-0.65	-0.79	-0.73	-0.94	-0.75
Accounts Payable	0.9	0.89	0.65	0.74	-0.88		0.87	0.75	0.86	0.79	0.85	0.71	0.83	-0.19	0.73	0.83	0.66	0.78	0.46	-0.43	0.49	0.79	0.89	0.7	0.85	0.81
Other Assets	0.81	0.8	0.86	0.84	-0.74	0.87		0.68	0.85	0.69	0.8	0.84	0.77	0.25	0.84	0.97	0.8	0.9	0.36	-0.7	0.74	0.66	1.0	0.82	0.81	0.97
Net Receivables	0.94	0.96	0.6	0.67	-0.95	0.75	0.68		0.77	0.99	0.95	0.64	0.97	-0.25	0.67	0.68	0.6	0.66	0.9	-0.47	0.55	0.46	0.74	0.66	0.9	0.7
Common Stock Shares Outstanding	0.85	0.86	0.8	0.72	-0.82	0.86	0.85	0.77		0.78	0.83	0.69	0.81	-0.09	0.71	0.8	0.64	0.74	0.54	-0.5	0.56	0.59	0.86	0.69	0.8	0.81
Other Current Assets	0.96	0.97	0.62	0.72	-0.97	0.79	0.69	0.99	0.78		0.97	0.69	0.99	-0.25	0.72	0.71	0.66	0.71	0.85	-0.5	0.58	0.56	0.75	0.71	0.94	0.72
Other Stockholder Equity	0.99	0.98	0.76	0.85	-0.97	0.85	0.8	0.95	0.83	0.97		0.83	1.0	-0.09	0.85	0.84	0.8	0.85	0.72	-0.64	0.71	0.69	0.85	0.84	0.99	0.84
Total Current Assets	0.77	0.74	0.93	0.99	-0.71	0.71	0.84	0.64	0.69	0.69	0.83		0.8	0.43	1.0	0.93	0.99	0.98	0.3	-0.93	0.95	0.72	0.84	1.0	0.88	0.93
Common Stock	0.98	0.98	0.73	0.82	-0.97	0.83	0.77	0.97	0.81	0.99	1.0	0.8		-0.12	0.82	0.81	0.77	0.82	0.77	-0.61	0.68	0.65	0.82	0.81	0.98	0.81
Property Plant Equipment	-0.2	-0.22	0.47	0.38	0.27	-0.19	0.25	-0.25	-0.09	-0.25	-0.09	0.43	-0.12		0.39	0.33	0.46	0.36	-0.4	-0.68	0.63	-0.04	0.19	0.41	-0.01	0.36
Total Assets	0.8	0.77	0.93	0.99	-0.74	0.73	0.84	0.67	0.71	0.72	0.85	1.0	0.82	0.39		0.94	0.99	0.99	0.32	-0.91	0.94	0.76	0.85	1.0	0.9	0.93
Short Long Term Debt Total	0.83	0.81	0.92	0.92	-0.74	0.83	0.97	0.68	0.8	0.71	0.84	0.93	0.81	0.33	0.94		0.92	0.98	0.33	-0.81	0.85	0.75	0.97	0.93	0.87	1.0
Total Stockholder Equity	0.74	0.7	0.92	0.98	-0.67	0.66	0.8	0.6	0.64	0.66	0.8	0.99	0.77	0.46	0.99	0.92		0.98	0.25	-0.94	0.95	0.74	0.81	1.0	0.86	0.91
Property Plant And Equipment Net	0.82	0.79	0.93	0.96	-0.74	0.78	0.9	0.66	0.74	0.71	0.85	0.98	0.82	0.36	0.99	0.98	0.98		0.3	-0.87	0.9	0.8	0.9	0.98	0.9	0.96
Current Deferred Revenue	0.71	0.75	0.29	0.35	-0.77	0.46	0.36	0.9	0.54	0.85	0.72	0.3	0.77	-0.4	0.32	0.33	0.25	0.3		-0.2	0.28	0.07	0.44	0.32	0.63	0.38
Net Debt	-0.53	-0.51	-0.9	-0.91	0.49	-0.43	-0.7	-0.47	-0.5	-0.5	-0.64	-0.93	-0.61	-0.68	-0.91	-0.81	-0.94	-0.87	-0.2		-0.99	-0.47	-0.69	-0.93	-0.7	-0.83
Cash	0.61	0.59	0.92	0.93	-0.56	0.49	0.74	0.55	0.56	0.58	0.71	0.95	0.68	0.63	0.94	0.85	0.95	0.9	0.28	-0.99		0.5	0.74	0.95	0.76	0.87
Non Current Assets Total	0.73	0.68	0.61	0.7	-0.65	0.79	0.66	0.46	0.59	0.56	0.69	0.72	0.65	-0.04	0.76	0.75	0.74	0.8	0.07	-0.47	0.5		0.68	0.72	0.76	0.68
Non Currrent Assets Other	0.86	0.86	0.86	0.85	-0.79	0.89	1.0	0.74	0.86	0.75	0.85	0.84	0.82	0.19	0.85	0.97	0.81	0.9	0.44	-0.69	0.74	0.68		0.84	0.85	0.98
Cash And Short Term Investments	0.78	0.75	0.93	0.99	-0.73	0.7	0.82	0.66	0.69	0.71	0.84	1.0	0.81	0.41	1.0	0.93	1.0	0.98	0.32	-0.93	0.95	0.72	0.84		0.89	0.92
Common Stock Total Equity	0.97	0.96	0.8	0.89	-0.94	0.85	0.81	0.9	0.8	0.94	0.99	0.88	0.98	-0.01	0.9	0.87	0.86	0.9	0.63	-0.7	0.76	0.76	0.85	0.89		0.87
Non Current Liabilities Total	0.82	0.81	0.93	0.92	-0.75	0.81	0.97	0.7	0.81	0.72	0.84	0.93	0.81	0.36	0.93	1.0	0.91	0.96	0.38	-0.83	0.87	0.68	0.98	0.92	0.87

Click cells to compare fundamentals

Gain Therapeutics Account Relationship Matchups

Gain Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	767.4K	1.2M	2.0M	2.1M	2.4M	2.5M
Total Current Liabilities	2.1M	2.6M	4.1M	4.9M	5.7M	6.0M
Other Liab	132.2K	171.6K	329.5K	157.6K	181.2K	179.3K
Net Tangible Assets	(450.0K)	6.2M	34.6M	18.7M	21.5M	12.8M
Retained Earnings	(7.0M)	(20.9M)	(38.5M)	(60.8M)	(54.7M)	(52.0M)
Accounts Payable	961.5K	560.5K	1.6M	1.3M	1.5M	874.7K
Other Assets	11.4K	63.8K	53.4K	48.3K	55.6K	41.4K
Net Receivables	66.6K	113.6K	103.9K	242.6K	279.0K	292.9K
Other Current Assets	71.0K	343.1K	399.8K	741.6K	852.9K	895.5K
Other Stockholder Equity	13.4M	55.8M	57.4M	73.1M	84.1M	88.3M
Total Current Assets	9.0M	37.7M	21.1M	17.8M	20.4M	15.9M
Property Plant Equipment	219.3K	552.7K	1.0M	144.4K	166.0K	157.7K
Total Assets	9.6M	39.0M	24.1M	18.6M	21.4M	20.2M
Short Long Term Debt Total	1.3M	1.6M	1.3M	1.0M	1.2M	1.2M
Total Stockholder Equity	6.2M	34.8M	18.9M	12.6M	14.5M	15.8M
Property Plant And Equipment Net	552.7K	1.0M	804.3K	585.2K	673.0K	697.1K
Current Deferred Revenue	239.5K	266.5K	55.2K	1.1M	1.3M	1.4M
Net Debt	(6.2M)	(35.3M)	(6.0M)	(10.8M)	(9.7M)	(10.2M)
Cash	7.5M	36.9M	7.3M	11.8M	13.6M	14.0M
Non Current Assets Total	616.5K	1.3M	3.0M	830.5K	955.0K	1.3M
Non Currrent Assets Other	63.8K	53.4K	48.3K	51.9K	59.7K	48.1K
Cash And Short Term Investments	7.5M	36.9M	20.1M	16.8M	19.3M	18.0M
Liabilities And Stockholders Equity	9.6M	39.0M	24.1M	18.6M	21.4M	20.2M
Non Current Liabilities Total	1.3M	1.6M	1.1M	1.1M	1.2M	1.2M
Capital Lease Obligations	523.1K	914.2K	670.9K	459.5K	528.5K	609.1K
Total Liab	3.4M	4.2M	5.2M	6.0M	6.9M	4.4M
Net Invested Capital	6.9M	35.5M	19.5M	13.1M	15.1M	16.4M
Property Plant And Equipment Gross	552.7K	1.0M	804.3K	678.0K	779.7K	717.5K
Accumulated Other Comprehensive Income	(152.7K)	(90.6K)	35.6K	247.2K	284.3K	298.5K
Net Working Capital	6.9M	35.2M	17.0M	12.8M	14.8M	15.7M
Short Term Debt	145.4K	542.1K	337.2K	348.5K	400.8K	324.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gain Historical Balance Sheet

Gain Therapeutics Inventory

1.64 Million

About Gain Balance Sheet Analysis

Gain Therapeutics Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Gain Therapeutics balance sheet Correlations

Gain Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Gain Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Gain Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Non Currrent Assets Other	+ 1.0	Other Assets
Common Stock	+ 1.0	Other Stockholder Equity
Total Assets	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Assets

Cash	- 0.99	Net Debt
Retained Earnings	- 0.98	Total Current Liabilities
Retained Earnings	- 0.98	Other Current Liab
Common Stock	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Other Current Assets	- 0.97	Retained Earnings